Lauren Feldman 2/03/2023 at 12:22 pm
Dazed Magazine (February 2, 2023) Will Harvard’s new bionic vaginas revolutionise women’s health?
Medical conditions affecting people with vulvas are notoriously understudied, but new developments in the field suggests this might be changing.
The ban aims to change the Food and Drugs Act to outlaw the sale of cosmetics that were tested on animals or contain animal-tested ingredients. These include products such as make-up, nail polish and perfume. Currently, the act does not require animal testing to demonstrate the safety of cosmetics. But Labchuk says stronger, mandatory language is needed in the legislation. The proposal is being developed by Health Canada — and according to The Globe and Mail, Health Minister Jean-Yves Duclos is poised to push the changes forward. The move would bring Canada in line with more than 40 countries that have limited or banned animal-tested cosmetics. But in a statement to The Current, Health Canada said no changes are expected to be finalized before August.
MIT News (January 30, 2023) “Spleen-on-a-chip” yields insight into sickle cell disease
With this microfluidic device, researchers modeled how sickled blood cells clog the spleen’s filters, leading to a potentially life-threatening condition.
Forbes (January 29, 2023) The Generative AI Revolution Is Creating The Next Phase Of Autonomous Enterprise
According to the Financial Times, investments in generative AI in 2022 exceeded $2 billion. OpenAI’s valuation for a potential sale of some shares was set at an impressive $29 billion by the Wall Street Journal. Clearly, this indicates the enormity of interest from investors and corporations in generative AI technology. As the world continues to embrace technology and automation, businesses are beginning to explore the infinite possibilities of Generative AI. This type of Artificial Intelligence is on the cusp of creating autonomous, self-sustaining digital-only enterprises that can interact with humans without the active need for human interaction.
Endpoint News (January 27, 2023) Novartis’ approved sickle cell disease drug fails to beat placebo in PhIII
Novartis’ sickle cell drug, approved in 2019 and branded as Adakveo, has failed an ongoing Phase III, according to preliminary results. The Swiss pharma giant unveiled early data from the ongoing STAND Phase III study on Friday, saying that crizanlizumab showed no statistically significant difference between the drug at two different dose levels compared to placebo in annualized rates of vaso-occlusive crises that lead to a healthcare visit over the first year since being randomized into the trial.
- You must be logged in to reply to this topic.